DATE CREATED: Jun28,2025  
Number of Observations: 585  
Number of Variables: 41

| **FileName** | **Variable\_label** | **Variable\_Name** | **Category** | **N\_\_Percent** | **Mean\_\_SD** | **Median\_Q1\_Q3** | **Range** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| visf | Blind\_id | Blind\_id |  | 119(100) |  |  |  |
| visf | Blinded\_SiteID | Blinded\_SiteID |  | 585(100) |  |  |  |
| visf | Visit Name | VISNAME | 1 Month Follow Up | 119(20.3) |  |  |  |
| visf | Visit Name | VISNAME | 12 Month Follow Up | 114(19.5) |  |  |  |
| visf | Visit Name | VISNAME | 18 Month Follow Up | 107(18.3) |  |  |  |
| visf | Visit Name | VISNAME | 24 Month Follow Up | 106(18.1) |  |  |  |
| visf | Visit Name | VISNAME | 3 Month Follow Up | 12(2.1) |  |  |  |
| visf | Visit Name | VISNAME | 6 Month Follow Up | 117(20) |  |  |  |
| visf | Visit Name | VISNAME | 9 Month Follow Up | 10(1.7) |  |  |  |
| visf | A1. Was the visit completed? | VISFYN | (Empty string) | 14(2.4) |  |  |  |
| visf | A1. Was the visit completed? | VISFYN | No | 29(5) |  |  |  |
| visf | A1. Was the visit completed? | VISFYN | Yes | 542(92.6) |  |  |  |
| visf | A1b. Type of follow-up | VISFTYP | (Empty string) | 43(7.4) |  |  |  |
| visf | A1b. Type of follow-up | VISFTYP | Clinic/office visit | 515(88) |  |  |  |
| visf | A1b. Type of follow-up | VISFTYP | Other | 3(0.5) |  |  |  |
| visf | A1b. Type of follow-up | VISFTYP | Parent/guardian contact | 2(0.3) |  |  |  |
| visf | A1b. Type of follow-up | VISFTYP | Telephone contact with subject | 22(3.8) |  |  |  |
| visf | A1b1. Specify the other follow-up type | VISFTYPO | (Empty string) | 582(99.5) |  |  |  |
| visf | A1b1. Specify the other follow-up type | VISFTYPO | PI and coordinator spoke to family/participant at non research clinic visit. Info collected. | 1(0.2) |  |  |  |
| visf | A1b1. Specify the other follow-up type | VISFTYPO | Remote visit -Telephone contact with parent and subject | 1(0.2) |  |  |  |
| visf | A1b1. Specify the other follow-up type | VISFTYPO | Virtual visit by telephone with Subject and Mother | 1(0.2) |  |  |  |
| visf | A1c. Was masking maintained since last visit through the completion of this visit and all associated assessments? | VISFMASK | (Empty string) | 43(7.4) |  |  |  |
| visf | A1c. Was masking maintained since last visit through the completion of this visit and all associated assessments? | VISFMASK | Yes | 542(92.6) |  |  |  |
| visf | A1d. If No, Reason | VISFNREAS | (Empty string) | 556(95) |  |  |  |
| visf | A1d. If No, Reason | VISFNREAS | Missed Visit | 4(0.7) |  |  |  |
| visf | A1d. If No, Reason | VISFNREAS | Subject Withdrawn | 25(4.3) |  |  |  |
| visf | A2. Were there any changes to existing adverse events/or new adverse events/ experienced since last visit? | VISFAEYN | (Empty string) | 43(7.4) |  |  |  |
| visf | A2. Were there any changes to existing adverse events/or new adverse events/ experienced since last visit? | VISFAEYN | No | 431(73.7) |  |  |  |
| visf | A2. Were there any changes to existing adverse events/or new adverse events/ experienced since last visit? | VISFAEYN | Yes | 111(19) |  |  |  |
| visf | A3. Did subject start study medication treatment since being randomized? | VISFSMTRT | (Empty string) | 468(80) |  |  |  |
| visf | A3. Did subject start study medication treatment since being randomized? | VISFSMTRT | No | 1(0.2) |  |  |  |
| visf | A3. Did subject start study medication treatment since being randomized? | VISFSMTRT | Yes | 116(19.8) |  |  |  |
| visf | A3b. Were there any changes to study medication since last visit? | VISFSMYN | (Empty string) | 43(7.4) |  |  |  |
| visf | A3b. Were there any changes to study medication since last visit? | VISFSMYN | No | 506(86.5) |  |  |  |
| visf | A3b. Were there any changes to study medication since last visit? | VISFSMYN | Yes | 36(6.2) |  |  |  |
| visf | A3c. Type of change | VISFSMCHG | (Empty string) | 549(93.8) |  |  |  |
| visf | A3c. Type of change | VISFSMCHG | Other | 6(1) |  |  |  |
| visf | A3c. Type of change | VISFSMCHG | Permanently discontinued | 16(2.7) |  |  |  |
| visf | A3c. Type of change | VISFSMCHG | Temporarily stopped | 14(2.4) |  |  |  |
| visf | A4. Were there any changes to existing or the addition of new concomitant medications, non-prescription medication, vitamins or herbal supplements/since last visit? | VISFCMYN | (Empty string) | 43(7.4) |  |  |  |
| visf | A4. Were there any changes to existing or the addition of new concomitant medications, non-prescription medication, vitamins or herbal supplements/since last visit? | VISFCMYN | No | 403(68.9) |  |  |  |
| visf | A4. Were there any changes to existing or the addition of new concomitant medications, non-prescription medication, vitamins or herbal supplements/since last visit? | VISFCMYN | Yes | 139(23.8) |  |  |  |
| visf | B1. Have there been any updates to the participant's family history of premature CVD since last visit? | VISFAMHX | (Empty string) | 43(7.4) |  |  |  |
| visf | B1. Have there been any updates to the participant's family history of premature CVD since last visit? | VISFAMHX | No | 534(91.3) |  |  |  |
| visf | B1. Have there been any updates to the participant's family history of premature CVD since last visit? | VISFAMHX | Unknown | 3(0.5) |  |  |  |
| visf | B1. Have there been any updates to the participant's family history of premature CVD since last visit? | VISFAMHX | Yes | 5(0.9) |  |  |  |
| visf | B1a. Did the total number of the participant's biological relatives with premature CVD change? | VISFHXCHG | (Empty string) | 580(99.1) |  |  |  |
| visf | B1a. Did the total number of the participant's biological relatives with premature CVD change? | VISFHXCHG | Yes | 5(0.9) |  |  |  |
| visf | B1a1. Total number of biological relatives with premature CVD | VISFHXNUM | 1 | 4(80) |  |  |  |
| visf | B1a1. Total number of biological relatives with premature CVD | VISFHXNUM | 3 | 1(20) |  |  |  |
| visf | B1a1. Total number of biological relatives with premature CVD | VISFHXNUM | <NA> | 580(NA) |  |  |  |
| visf | C1. Unexplained and/or persistent muscle pain, tenderness or weakness | SYMMUSCL | (Empty string) | 43(7.4) |  |  |  |
| visf | C1. Unexplained and/or persistent muscle pain, tenderness or weakness | SYMMUSCL | No | 530(90.6) |  |  |  |
| visf | C1. Unexplained and/or persistent muscle pain, tenderness or weakness | SYMMUSCL | Unknown | 1(0.2) |  |  |  |
| visf | C1. Unexplained and/or persistent muscle pain, tenderness or weakness | SYMMUSCL | Yes | 11(1.9) |  |  |  |
| visf | C1a. Is the Unexplained and/or persistent muscle pain, tenderness or weakness/ associated with recent physical activity or any recent trauma or injury? | SYMUSCINJ | (Empty string) | 574(98.1) |  |  |  |
| visf | C1a. Is the Unexplained and/or persistent muscle pain, tenderness or weakness/ associated with recent physical activity or any recent trauma or injury? | SYMUSCINJ | No | 7(1.2) |  |  |  |
| visf | C1a. Is the Unexplained and/or persistent muscle pain, tenderness or weakness/ associated with recent physical activity or any recent trauma or injury? | SYMUSCINJ | Unknown | 2(0.3) |  |  |  |
| visf | C1a. Is the Unexplained and/or persistent muscle pain, tenderness or weakness/ associated with recent physical activity or any recent trauma or injury? | SYMUSCINJ | Yes | 2(0.3) |  |  |  |
| visf | C2. Brown or red urine | SYMURINE | (Empty string) | 43(7.4) |  |  |  |
| visf | C2. Brown or red urine | SYMURINE | No | 538(92) |  |  |  |
| visf | C2. Brown or red urine | SYMURINE | Unknown | 3(0.5) |  |  |  |
| visf | C2. Brown or red urine | SYMURINE | Yes | 1(0.2) |  |  |  |
| visf | C3. Appearance of fatigue | SYMFATIG | (Empty string) | 43(7.4) |  |  |  |
| visf | C3. Appearance of fatigue | SYMFATIG | No | 516(88.2) |  |  |  |
| visf | C3. Appearance of fatigue | SYMFATIG | Unknown | 1(0.2) |  |  |  |
| visf | C3. Appearance of fatigue | SYMFATIG | Yes | 25(4.3) |  |  |  |
| visf | C4. Nausea and/or Vomiting | SYMNAUS | (Empty string) | 43(7.4) |  |  |  |
| visf | C4. Nausea and/or Vomiting | SYMNAUS | No | 519(88.7) |  |  |  |
| visf | C4. Nausea and/or Vomiting | SYMNAUS | Unknown | 2(0.3) |  |  |  |
| visf | C4. Nausea and/or Vomiting | SYMNAUS | Yes | 21(3.6) |  |  |  |
| visf | C5. Right upper quadrant pain or tenderness | SYMPAIN | (Empty string) | 43(7.4) |  |  |  |
| visf | C5. Right upper quadrant pain or tenderness | SYMPAIN | No | 535(91.5) |  |  |  |
| visf | C5. Right upper quadrant pain or tenderness | SYMPAIN | Unknown | 2(0.3) |  |  |  |
| visf | C5. Right upper quadrant pain or tenderness | SYMPAIN | Yes | 5(0.9) |  |  |  |
| visf | C6. Eosinophilia (> 5%) | SYMEOSIN | (Empty string) | 43(7.4) |  |  |  |
| visf | C6. Eosinophilia (> 5%) | SYMEOSIN | No | 428(73.2) |  |  |  |
| visf | C6. Eosinophilia (> 5%) | SYMEOSIN | Unknown | 111(19) |  |  |  |
| visf | C6. Eosinophilia (> 5%) | SYMEOSIN | Yes | 3(0.5) |  |  |  |
| visf | C7. Elevations in liver enzymes | SYMLIVER | (Empty string) | 43(7.4) |  |  |  |
| visf | C7. Elevations in liver enzymes | SYMLIVER | No | 443(75.7) |  |  |  |
| visf | C7. Elevations in liver enzymes | SYMLIVER | Unknown | 35(6) |  |  |  |
| visf | C7. Elevations in liver enzymes | SYMLIVER | Yes | 64(10.9) |  |  |  |
| visf | C8. Yellow skin or eye discoloration (jaundice) | SYMJAUND | (Empty string) | 43(7.4) |  |  |  |
| visf | C8. Yellow skin or eye discoloration (jaundice) | SYMJAUND | No | 541(92.5) |  |  |  |
| visf | C8. Yellow skin or eye discoloration (jaundice) | SYMJAUND | Unknown | 1(0.2) |  |  |  |
| visf | C9. Frequent or night-time urination, excessive fatigue and/or excessive thirst | SYMTHRST | (Empty string) | 43(7.4) |  |  |  |
| visf | C9. Frequent or night-time urination, excessive fatigue and/or excessive thirst | SYMTHRST | No | 527(90.1) |  |  |  |
| visf | C9. Frequent or night-time urination, excessive fatigue and/or excessive thirst | SYMTHRST | Unknown | 1(0.2) |  |  |  |
| visf | C9. Frequent or night-time urination, excessive fatigue and/or excessive thirst | SYMTHRST | Yes | 14(2.4) |  |  |  |
| visf | C10. Rash and itching | SYMRASH | (Empty string) | 43(7.4) |  |  |  |
| visf | C10. Rash and itching | SYMRASH | No | 524(89.6) |  |  |  |
| visf | C10. Rash and itching | SYMRASH | Unknown | 1(0.2) |  |  |  |
| visf | C10. Rash and itching | SYMRASH | Yes | 17(2.9) |  |  |  |
| visf | C11. Diarrhea | SYMDIAR | (Empty string) | 43(7.4) |  |  |  |
| visf | C11. Diarrhea | SYMDIAR | No | 523(89.4) |  |  |  |
| visf | C11. Diarrhea | SYMDIAR | Unknown | 2(0.3) |  |  |  |
| visf | C11. Diarrhea | SYMDIAR | Yes | 17(2.9) |  |  |  |
| visf | C12. Constipation | SYMCONST | (Empty string) | 43(7.4) |  |  |  |
| visf | C12. Constipation | SYMCONST | No | 527(90.1) |  |  |  |
| visf | C12. Constipation | SYMCONST | Unknown | 1(0.2) |  |  |  |
| visf | C12. Constipation | SYMCONST | Yes | 14(2.4) |  |  |  |
| visf | D1. Was pregnancy/contraceptive counseling discussed with the subject at this visit? | PREG\_CON | (Empty string) | 44(7.5) |  |  |  |
| visf | D1. Was pregnancy/contraceptive counseling discussed with the subject at this visit? | PREG\_CON | No | 183(31.3) |  |  |  |
| visf | D1. Was pregnancy/contraceptive counseling discussed with the subject at this visit? | PREG\_CON | Yes | 358(61.2) |  |  |  |
| visf | D2. Did subject confirm abstinence or use of contraceptives measures? | ABS\_CONTRA | (Empty string) | 44(7.5) |  |  |  |
| visf | D2. Did subject confirm abstinence or use of contraceptives measures? | ABS\_CONTRA | No | 180(30.8) |  |  |  |
| visf | D2. Did subject confirm abstinence or use of contraceptives measures? | ABS\_CONTRA | Yes | 361(61.7) |  |  |  |
| visf | E1. Preventive Cardiology Lifestyle Screener Questionnaire | LIFESTYN | (Empty string) | 277(47.4) |  |  |  |
| visf | E1. Preventive Cardiology Lifestyle Screener Questionnaire | LIFESTYN | No | 4(0.7) |  |  |  |
| visf | E1. Preventive Cardiology Lifestyle Screener Questionnaire | LIFESTYN | Yes | 304(52) |  |  |  |
| visf | E2. Pittsburgh Sleep Quality Index | PSQIYN | (Empty string) | 277(47.4) |  |  |  |
| visf | E2. Pittsburgh Sleep Quality Index | PSQIYN | No | 4(0.7) |  |  |  |
| visf | E2. Pittsburgh Sleep Quality Index | PSQIYN | Yes | 304(52) |  |  |  |
| visf | E3. Was data obtained from the Fitbit physical activity tracker device? | FBITYN | (Empty string) | 160(27.4) |  |  |  |
| visf | E3. Was data obtained from the Fitbit physical activity tracker device? | FBITYN | No | 203(34.7) |  |  |  |
| visf | E3. Was data obtained from the Fitbit physical activity tracker device? | FBITYN | Yes | 222(37.9) |  |  |  |
| visf | E4. Tanner staging (self report) | TANSYN | (Empty string) | 277(47.4) |  |  |  |
| visf | E4. Tanner staging (self report) | TANSYN | No | 11(1.9) |  |  |  |
| visf | E4. Tanner staging (self report) | TANSYN | Yes | 297(50.8) |  |  |  |
| visf | E5. Labs | LABYN | (Empty string) | 43(7.4) |  |  |  |
| visf | E5. Labs | LABYN | No | 10(1.7) |  |  |  |
| visf | E5. Labs | LABYN | Yes | 532(90.9) |  |  |  |
| visf | E6. Anthropometry, blood pressure measurements | ANTHROPYN | (Empty string) | 169(28.9) |  |  |  |
| visf | E6. Anthropometry, blood pressure measurements | ANTHROPYN | No | 12(2.1) |  |  |  |
| visf | E6. Anthropometry, blood pressure measurements | ANTHROPYN | Yes | 404(69.1) |  |  |  |
| visf | E7. Vascular measures (PWV, CIMT, carotid stiffness) | VASCMYN | (Empty string) | 196(33.5) |  |  |  |
| visf | E7. Vascular measures (PWV, CIMT, carotid stiffness) | VASCMYN | No | 28(4.8) |  |  |  |
| visf | E7. Vascular measures (PWV, CIMT, carotid stiffness) | VASCMYN | Yes | 361(61.7) |  |  |  |
| visf | A1a. Age at Date of contact | VISFAge |  | 542(93) | 15.05(2.5) | 14.71(13.06,17.12) | 10.13,21.66 |
| visf | A3a. Age at Date First Dose taken | VISFSMAge |  | 116(20) | 13.98(2.5) | 13.59(11.92,15.88) | 10,19.65 |
| visf | C1b. Age at Date of first new muscle symptom | SYMUSAge |  | 10(2) | 15.27(2.4) | 15.83(13.64,16.47) | 10.94,19.25 |